: To report on our experience with the use of an evidence-based algorithm defining specific indications for stent omission (SO) after ureteroscopic lithotripsy (URSL), as stent placement has been associated with increased cost and morbidity and indications for SO in the setting of uncomplicated ureteroscopy have been proposed but remain vague. : Indications for SO were defined as per the attached figure, data from URSL procedures performed from January 2016 to September 2017 were collected. For procedures eligible for SO, preoperative and intraoperative factors were recorded including: stone burden, presence of preoperative stent, procedure time, access sheath use, and whether SO was performed. Morbidity data were reviewed including: postoperative events, patient telephone calls for bothersome symptoms, unplanned return visits, and admissions within 30 days. : In all, 250 URSL procedures were performed during the study period, and 106 (42.4%) were eligible for SO. SO was performed in 60 (24.0%) cases reflecting a 56.7% compliance with the algorithm. There were no readmissions or re-operations within 30 days for the SO group. Lower postoperative event rates were noted in the SO group (16.7% vs 34.8%, = 0.03), unplanned return visits (8.3% vs 17.4%, = 0.16) and 30-day readmission rates (0.0% vs 6.5%, = 0.08) were also lower in the SO group, although they did not reach statistical significance. Analysis also demonstrated a protective effect of SO on unplanned return visits (odds ratio 0.43, 95% confidence interval 0.13-1.42, = 0.17), although this was not statistically significant. No statistically significant associations were noted between postoperative events and stone burden, procedure time, or presence of preoperative stent. : We provide an algorithm defining indications for SO. SO is safe in a significant portion of URSL procedures, and SO appears to decrease postoperative events when performed judiciously. IQR: interquartile range; LUTS: lower urinary tract symptoms; OR, odds ratio; SO: stent omission; URSL: ureteroscopic lithotripsy; YAG: yttrium-aluminium-garnet.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711146PMC
http://dx.doi.org/10.1080/2090598X.2019.1614243DOI Listing

Publication Analysis

Top Keywords

stent omission
12
ureteroscopic lithotripsy
12
ursl procedures
12
postoperative events
12
unplanned return
12
return visits
12
indications stent
8
omission ureteroscopic
8
algorithm defining
8
procedures performed
8

Similar Publications

Purpose: Ureteral stents are commonly placed intraoperatively during radical cystectomy, although their efficacy in reducing complications is unproven. We compared clinical outcomes among patients undergoing robot-assisted radical cystectomy with intracorporeal ileal conduit (RARC-IC) with or without ureteral stents to determine if omission of ureteral stents affects postoperative complications.

Materials And Methods: All RARC-IC surgeries performed at our institution between November 2017 and June 2023 were reviewed.

View Article and Find Full Text PDF
Article Synopsis
  • - Ureteral stents are commonly used after ureteroscopy to prevent complications from kidney stones, yet they can cause significant pain and urinary issues, which has led to calls for their omission in many cases.
  • - Guidelines support not using stents in uncomplicated surgeries, but over 80% of procedures still involve them, partly due to insufficient evidence about their impact on pain and patient outcomes.
  • - A new study is being conducted where patients randomly choose whether to have a stent or not, while those who refuse randomization will be observed based on the doctor's decision, aiming to gather real-world data on the effectiveness of stent omission.
View Article and Find Full Text PDF
Article Synopsis
  • The optimal management of patients with atrial fibrillation (AF) requiring oral anticoagulation (OAC) during percutaneous coronary intervention (PCI) is debated, with current guidelines suggesting a temporary triple therapy regimen that includes aspirin, which raises bleeding risks.
  • A new study, the WOEST-3 trial, seeks to compare a 30-day dual antiplatelet therapy (DAPT) strategy that temporarily omits OAC against guideline-directed therapy post-PCI for AF patients, aiming to reduce bleeding without sacrificing efficacy.
  • With a sample of 2,000 patients, the trial will evaluate the rates of major bleeding and adverse ischemic events, making it the first randomized controlled trial to explore the omission of OAC
View Article and Find Full Text PDF

Aspirin hypersensitivity: a practical guide for cardiologists.

Eur Heart J

May 2024

Postgraduate School of Cardiology, University of Pisa and Cardiovascular Division, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy.

Aspirin has been known for a long time and currently stays as a cornerstone of antithrombotic therapy in cardiovascular disease. In patients with either acute or chronic coronary syndromes undergoing percutaneous coronary intervention aspirin is mandatory in a dual antiplatelet therapy regimen for prevention of stent thrombosis and/or new ischaemic events. Aspirin is also currently a first-option antithrombotic therapy after an aortic prosthetic valve replacement and is occasionally required in addition to oral anticoagulants after implantation of a mechanical valve.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!